BridgeBio Pharma's Participation in Investor Conferences
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is set to actively engage with investors in November, taking part in prominent healthcare investor conferences. These events represent a significant opportunity for the company to share its advancements in treating genetic diseases and connect with stakeholders in the healthcare community.
Upcoming Conference Details
The management team of BridgeBio will be hosting fireside chats at two major conferences this November:
UBS Global Healthcare Conference
This event will take place on November 10 at 1:15 PM EST. Attendees will gain insights into BridgeBio's innovative approach to biopharmaceuticals and their commitment to finding solutions for genetic disorders.
Jefferies Global Healthcare Conference
Following UBS, the company will participate in the Jefferies Global Healthcare Conference on November 18 at 11:00 AM EST. This chat is anticipated to highlight the latest developments and research pipeline that BridgeBio has in process, reflecting their tireless efforts in the realm of genetic medicine.
Accessing Live Webcasts
For those interested in accessing live presentations during these events, BridgeBio has made it easy. During the conferences, investors can tune into the webcasts available on the "Events and Presentations" page of the BridgeBio website. This ensures that everyone has the opportunity to stay informed about the company's strategic direction and development processes.
About BridgeBio Pharma, Inc.
Founded to transform the treatment landscape for genetic diseases, BridgeBio Pharma is a pioneering biopharmaceutical company. The company has a robust pipeline that includes various programs spanning from early-stage research to advanced clinical trials. BridgeBio's focus on genetic medicine positions it uniquely in the healthcare industry, allowing for timely responses to unmet medical needs.
The company holds a strong commitment to innovation, driven by a team of seasoned professionals dedicated to creating and delivering groundbreaking therapies as efficiently as possible.
BridgeBio's Communication Channels
BridgeBio encourages interested parties to keep in touch through its corporate website. Individuals can find further information about the company's initiatives and achievements. Stay connected by following them on various social media platforms for the latest updates and announcements.
BridgeBio Media Contact
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
Frequently Asked Questions
What is BridgeBio Pharma's focus area?
BridgeBio Pharma specializes in developing treatments for genetic diseases through innovative biopharmaceutical approaches.
When are the upcoming investor conferences?
The conferences are scheduled for November 10 and November 18.
How can investors access the live presentations?
Investors can access live webcasts through the "Events and Presentations" section on the BridgeBio website.
What is the significance of these conferences for BridgeBio?
The conferences allow BridgeBio to present its cutting-edge research and connect with investors, showcasing its commitment to advancing genetic medicine.
Who is the media contact at BridgeBio Pharma?
Bubba Murarka serves as the media contact and can be reached at the company's official email address.